首页|Research advances of nanoparticles for CAR-T therapy in solid tumors
Research advances of nanoparticles for CAR-T therapy in solid tumors
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
万方数据
维普
As one of the most promising adoptive T-cell therapies,chimeric antigen receptor T-cell(CAR-T)therapy has acquired Food and Drug Administration(FDA)approval for a variety of products and has been used successfully in the treatment of malignant hematological tumors.CAR-T therapy,on the other hand,faces a number of obstacles in the field of solid tumor therapy that limit its widespread clinical implemen-tation.Significant advances in nanoparticle research in cancer therapy and immunotherapy have been made in recent years,providing novel strategies to address the challenges encountered by CAR-T therapy in the treatment of solid tumors.This review commences with a comprehensive explanation of the basic framework of CAR-T therapy as well as the challenges it faces in the treatment of solid tumors.Subse-quently,we encapsulate a summary of the developmental research combining nanoparticles with CAR-T cells for the treatment of solid tumors,which includes gene transfection,cell activation and expansion,targeted infiltration,immune escape inhibition,and combination with other therapies.Coupled with the overview of the research progress,a discussion has been initiated on the challenges and perspectives of CAR-T based on nanoparticles.
State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Department of Pharmaceutics,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China
School of Pharmacy,Qingdao University,Qingdao 266071,China
万方数据
维普
